Skip to Content
Merck
CN

SML4197

Eltrombopag olamine

≥98% (HPLC)

Synonym(s):

3′-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid, bis-(monoethanolamine), (Z)-3′-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2′-hydroxybiphenyl-3-carboxylic acid, bis-(monoethanolamine), SB 497115 bis-(ethanolamine) salt, SB-497115 bis-(ethanolamine) salt, SB497115 bis-(ethanolamine) salt

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C25H22N4O4·2C2H7NO
CAS Number:
Molecular Weight:
564.63
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

light brown-red to very dark brown-red

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

Biochem/physiol Actions

Orally active, potent and selective thrombopoietin (Tpo) receptor (TpoR) agonist in vitro and in vivo.
Eltrombopag is an orally active nonpeptide thrombopoietin receptor (TpoR) agonist that selectively induces STAT activation and proliferation (EC50 = 270 & 30 nM, respectively) of hToR-transfected, but not non-transfected, BAF3 cells. Eltrombopag increases the differentiation of primary human CD34(+) bone marrow cells into CD41(+) megakaryocytes ex vivo (EC50 = 100 nM) and exhibits thrombopoietic activity in chimpanzees in vivo (10 mg/kg/day p.o.).

Disclaimer

Hygroscopic Store with dessicant

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Connie L Erickson-Miller et al.
Stem cells (Dayton, Ohio), 27(2), 424-430 (2008-11-29)
Eltrombopag is a first-in-class, orally bioavailable, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), which is being developed as a treatment for thrombocytopenia of various etiologies. In vitro studies have demonstrated that the activity of eltrombopag is dependent on expression
Gabriel Levy et al.
Blood, 135(12), 948-953 (2020-01-25)
Mutations in the MPL gene encoding the human thrombopoietin receptor (TpoR) drive sporadic and familial essential thrombocythemias (ETs). We identified 2 ET patients harboring double mutations in cis in MPL, namely, L498W-H499C and H499Y-S505N. Using biochemical and signaling assays along
Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication
Waters T, et al.
BMC Cancer, 20 (2020)
Darren Kelly et al.
Journal of veterinary internal medicine, 34(2), 890-892 (2020-02-26)
Idiopathic aplastic pancytopenia is an uncommon disease in dogs which results in pancytopenia and for which an immune-mediated etiology is suspected. A small number of affected dogs reported in the veterinary literature have responded to immunosuppressive medication but the prognosis
Gavin C Sampey et al.
Viruses, 12(10) (2020-09-27)
Human immunodeficiency virus 1 (HIV-1) is the most prevalent human retrovirus. Recent data show that 34 million people are living with HIV-1 worldwide. HIV-1 infections can lead to AIDS which still causes nearly 20,000 deaths annually in the USA alone.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service